SEC Comment Letter for Lakewood-Amedex Biotherapeutics (LABT) — May 8, 2026
Lakewood-Amedex Biotherapeutics Inc.
Date: May 8, 2026 · CIK: 0002079272 · Accession: 0000000000-26-004726
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295497
Letter
Re: Lakewood-Amedex Biotherapeutics Inc. Registration Statement on Form S-1 Filed May 01, 2026 File No. 333-295497 Dear Kelvin Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions.
May 8, 2026
Kelvin Cooper Chief Executive Officer Lakewood-Amedex Biotherapeutics Inc. 8031 Cooper Creek Blvd., Unit 103 University Park, Fl 34201
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Scott Linsky, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> May 8, 2026 Kelvin Cooper Chief Executive Officer Lakewood-Amedex Biotherapeutics Inc. 8031 Cooper Creek Blvd., Unit 103 University Park, Fl 34201 Re: Lakewood-Amedex Biotherapeutics Inc. Registration Statement on Form S-1 Filed May 01, 2026 File No. 333-295497 Dear Kelvin Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Scott Linsky, Esq. </TEXT> </DOCUMENT>